These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 29651552)

  • 1. Prevention of High-Level Daptomycin-Resistance Emergence In Vitro in Streptococcus mitis-oralis by Using Combination Antimicrobial Strategies.
    Zapata B; Alvarez DN; Farah S; Garcia-de-la-Maria C; Miro JM; Sakoulas G; Bayer AS; Mishra NN
    Curr Microbiol; 2018 Aug; 75(8):1062-1067. PubMed ID: 29651552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Daptomycin Dose-Ranging Evaluation with Single-Dose versus Multidose Ceftriaxone Combinations against Streptococcus mitis
    Kebriaei R; Rice SA; Stamper KC; Seepersaud R; Garcia-de-la-Maria C; Mishra NN; Miro JM; Arias CA; Tran TT; Sullam PM; Bayer AS; Rybak MJ
    Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962347
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinations of Daptomycin plus Ceftriaxone, but Not Ascending Daptomycin Dose-Regimens, Are Effective in Experimental Endocarditis Caused by Streptococcus mitis
    Mishra NN; Abdelhady W; Elsayed AM; Lapitan C; Proctor RA; Rybak MJ; Miro JM; Bayer AS
    Antimicrob Agents Chemother; 2023 Apr; 67(4):e0147222. PubMed ID: 36877026
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perturbations of Phosphatidate Cytidylyltransferase (CdsA) Mediate Daptomycin Resistance in Streptococcus mitis/oralis by a Novel Mechanism.
    Mishra NN; Tran TT; Seepersaud R; Garcia-de-la-Maria C; Faull K; Yoon A; Proctor R; Miro JM; Rybak MJ; Bayer AS; Arias CA; Sullam PM
    Antimicrob Agents Chemother; 2017 Apr; 61(4):. PubMed ID: 28115347
    [No Abstract]   [Full Text] [Related]  

  • 5. Mutations in
    Tran TT; Mishra NN; Seepersaud R; Diaz L; Rios R; Dinh AQ; Garcia-de-la-Maria C; Rybak MJ; Miro JM; Shelburne SA; Sullam PM; Bayer AS; Arias CA
    Antimicrob Agents Chemother; 2019 Feb; 63(2):. PubMed ID: 30509945
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early in vitro and in vivo development of high-level daptomycin resistance is common in mitis group Streptococci after exposure to daptomycin.
    García-de-la-Mària C; Pericas JM; Del Río A; Castañeda X; Vila-Farrés X; Armero Y; Espinal PA; Cervera C; Soy D; Falces C; Ninot S; Almela M; Mestres CA; Gatell JM; Vila J; Moreno A; Marco F; Miró JM;
    Antimicrob Agents Chemother; 2013 May; 57(5):2319-25. PubMed ID: 23478959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of High-Level Daptomycin Resistance in the Streptococcus mitis Group on Virulence and Survivability during Daptomycin Treatment in Experimental Infective Endocarditis.
    Garcia-de-la-Maria C; Xiong YQ; Pericas JM; Armero Y; Moreno A; Mishra NN; Rybak MJ; Tran TT; Arias CA; Sullam PM; Bayer AS; Miro JM
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28264848
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Impact of Daptomycin Dose Exposure Alone or in Combination with β-Lactams or Rifampin against Vancomycin-Resistant Enterococci in an
    Jahanbakhsh S; Singh NB; Yim J; Kebriaei R; Smith JR; Lev K; Tran TT; Rose WE; Arias CA; Rybak MJ
    Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094136
    [No Abstract]   [Full Text] [Related]  

  • 9. Novel daptomycin combinations against daptomycin-nonsusceptible methicillin-resistant Staphylococcus aureus in an in vitro model of simulated endocardial vegetations.
    Steed ME; Vidaillac C; Rybak MJ
    Antimicrob Agents Chemother; 2010 Dec; 54(12):5187-92. PubMed ID: 20921318
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of daptomycin combinations with cephalosporins or gentamicin against Streptococcus mitis group strains in an in vitro model of simulated endocardial vegetations (SEVs).
    Yim J; Smith JR; Singh NB; Rice S; Stamper K; Garcia de la Maria C; Bayer AS; Mishra NN; Miró JM; Tran TT; Arias CA; Sullam P; Rybak MJ
    J Antimicrob Chemother; 2017 Aug; 72(8):2290-2296. PubMed ID: 28475731
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Streptococcus mitis and S. oralis Lack a Requirement for CdsA, the Enzyme Required for Synthesis of Major Membrane Phospholipids in Bacteria.
    Adams HM; Joyce LR; Guan Z; Akins RL; Palmer KL
    Antimicrob Agents Chemother; 2017 May; 61(5):. PubMed ID: 28223392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.
    Smith JR; Barber KE; Raut A; Rybak MJ
    Antimicrob Agents Chemother; 2015 May; 59(5):2842-8. PubMed ID: 25753639
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of the synergistic effect of ceftaroline against methicillin-resistant Staphylococcus aureus.
    Tsai CE; Yang CJ; Chuang YC; Wang JT; Sheng WH; Chen YC; Chang SC
    Int J Infect Dis; 2022 Sep; 122():230-236. PubMed ID: 35640827
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bactericidal activity of penicillin, ceftriaxone, gentamicin and daptomycin alone and in combination against Aerococcus urinae.
    Hirzel C; Hirzberger L; Furrer H; Endimiani A
    Int J Antimicrob Agents; 2016 Sep; 48(3):271-6. PubMed ID: 27451085
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mechanistic Fingerprinting Reveals Kinetic Signatures of Resistance to Daptomycin and Host Defense Peptides in
    Yeaman MR; Chan LC; Mishra NN; Bayer AS
    Antibiotics (Basel); 2021 Apr; 10(4):. PubMed ID: 33918000
    [No Abstract]   [Full Text] [Related]  

  • 16. Evaluation of Ceftaroline Alone and in Combination against Biofilm-Producing Methicillin-Resistant Staphylococcus aureus with Reduced Susceptibility to Daptomycin and Vancomycin in an In Vitro Pharmacokinetic/Pharmacodynamic Model.
    Barber KE; Smith JR; Ireland CE; Boles BR; Rose WE; Rybak MJ
    Antimicrob Agents Chemother; 2015 Aug; 59(8):4497-503. PubMed ID: 25987623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolic changes associated with adaptive resistance to daptomycin in Streptococcus mitis-oralis.
    Parrett A; Reed JM; Gardner SG; Mishra NN; Bayer AS; Powers R; Somerville GA
    BMC Microbiol; 2020 Jun; 20(1):162. PubMed ID: 32539684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of tedizolid against Staphylococcus aureus and enterococci with reduced susceptibility to vancomycin, daptomycin or linezolid.
    Barber KE; Smith JR; Raut A; Rybak MJ
    J Antimicrob Chemother; 2016 Jan; 71(1):152-5. PubMed ID: 26476277
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Strain-Specific Adaptations of
    Mishra NN; Tran TT; Arias CA; Seepersaud R; Sullam PM; Bayer AS
    Antibiotics (Basel); 2020 Aug; 9(8):. PubMed ID: 32824132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo development of daptomycin resistance in vancomycin-susceptible methicillin-resistant Staphylococcus aureus severe infections previously treated with glycopeptides.
    Capone A; Cafiso V; Campanile F; Parisi G; Mariani B; Petrosillo N; Stefani S
    Eur J Clin Microbiol Infect Dis; 2016 Apr; 35(4):625-31. PubMed ID: 26815434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.